Register for email alerts and news feeds:
This journal | BMJ Group
rss
Annals of the Rheumatic Diseases 2001;60:846-851
Copyright © 2001 BMJ Publishing Group Ltd & European League Against Rheumatism.
Ann Rheum Dis 2001;60:846-851 ( September )

Extended report

Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls S A Young-Mina, C Beetonb, R Laughtona, T Plumptonb, S Bartramc, G Murphyd, C Blacke, T E Cawstona

a Department of Rheumatology, University of Newcastle-upon-Tyne, UK, b School of Clinical Medicine, University of Cambridge, UK, c Department of Rheumatology, Newcastle-upon-Tyne NHS Hospitals Trust, UK, d University of East Anglia, UK, e Department of Rheumatology, Royal Free Hospital, London, UK

Correspondence to: Dr S A Young-Min, Rheumatology, School of Clinical and Medical Sciences, The Medical School, Catherine Cookson Building, University of Newcastle-upon-Tyne NE2 4HH, UK Steven.youngMin{at}ncl.ac.uk

Accepted for publication 31 January 2001

BACKGROUND---Excess tissue matrix accumulates in systemic sclerosis (SSc), accounting for both visceral and dermal fibrosis. It is suggested that decreased serum levels of matrix metalloproteinases (MMPs) or increased levels of tissue inhibitors of matrix metalloproteinases (TIMPs) may account for this matrix accumulation.
OBJECTIVE---To measure serum levels of tissue inhibitors of metalloproteinases, TIMP-1, TIMP-2, and collagenase-1 (MMP-1), in patients with diffuse cutaneous systemic sclerosis (dcSSc), limited cutaneous systemic sclerosis (lcSSc), primary Raynaud's phenomenon (RP), and in normal controls.
METHODS---Serum samples from patients with dcSSc (n=83), lcSSc (n=87), RP (n=80), and normal controls (n=98) were analysed using enzyme linked immunosorbent assays (ELISAs) for total TIMP-1, TIMP-2, and MMP-1. Results from each assay were analysed by the Kruskal-Wallis test. Dunn's multiple comparison post-test was then applied between groups.
RESULTS---TIMP-1 levels were significantly raised in dcSSc and lcSSc groups compared with the RP group and normal controls (p<0.01 to p<0.001). In the dcSSc group, TIMP-1 levels were significantly higher in early disease (<2 years) than in late stage disease (>4 years) (p<0.05). This was not found for the lcSSc group. Serum TIMP-2 and MMP-1 levels in dcSSc and lcSSc did not differ significantly from those in normal controls. Increased levels of TIMPs were not convincingly associated with organ disease. No assay result correlated with autoantibody status (anti-topoisomerase 1 (anti-Scl-70), anticentromere antibody, or anti-RNA polymerase). No significant differences in serum TIMP-1, TIMP-2, or MMP-1 levels were shown in the RP group compared with normal controls.
CONCLUSIONS---Raised TIMP-1 levels in the SSc groups support the hypothesis that matrix accumulation occurs in SSc at least in part owing to decreased degradation. Moreover, the variation in TIMP-1 levels between the early and late disease stages of dcSSc seems to reflect the early progressive course of dermal fibrosis seen clinically. The expected reduction in serum MMP-1 levels in the SSc groups was not found. This suggests that tissue matrix accumulation is due to increased inhibitors rather than to decreased MMPs.


© 2001 by Annals of the Rheumatic Diseases

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • BLAISE, S., MAAS, R., TROCME, C., KOM, G. D., ROUSTIT, M., CARPENTIER, P. H., CRACOWSKI, J.-L. (2009). Correlation of Biomarkers of Endothelium Dysfunction and Matrix Remodeling in Patients with Systemic Sclerosis. The Journal of Rheumatology 36: 984-988 [Abstract] [Full Text]  
  • Nikkola, J., Vihinen, P., Vuoristo, M.-S., Kellokumpu-Lehtinen, P., Kahari, V.-M., Pyrhonen, S. (2005). High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma. Clin. Cancer Res. 11: 5158-5166 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs